Lightnews — Scholar-powered news

Fotios Barkas @fotiosbarkas.bsky.social · 1d

Webinar | 🗓️ 20/10/25, 18:00 (Zoom)
Από τις Οδηγίες 2019 ➜ 2025:
Τι αλλάζει στη διαχείριση των δυσλιπιδαιμιών;

🎙️ Ε. Λυμπερόπουλος | Χ. Μηλιώνης
👨‍⚕️ Προεδρείο: Φ. Μπάρκας

🔗 Εγγραφή: bit.ly/has-lipids202
#Lipids #Cardiology #HAS #EAS #Webinar

Fotios Barkas @fotiosbarkas.bsky.social · 1d

Evidence-based, scalable & practical — a path to change the #ASCVD trajectory.

1

Fotios Barkas @fotiosbarkas.bsky.social · 1d

Keypoints: ✅ Start early with potent oral combination therapy in high-risk or #ASCVD patients. ✅ Escalate to triple therapy (PCSK9-targeted agents or bempedoic acid) if not at target. ✅ Follow-up, adherence & optimization are key.

1 1

Fotios Barkas @fotiosbarkas.bsky.social · 1d

👉 doi.org/10.1093/eurheartj/eh...

1

Fotios Barkas @fotiosbarkas.bsky.social · 1d

Let’s fight back years of inertia in #lipid management by shifting from reactive “treat-and-wait” care to a proactive “Fire-and-Forget” approach — ensuring early, potent & sustained #LDL-C reduction!
Delighted to share our new paper published in the European Heart Journal.

1 1

Fotios Barkas @fotiosbarkas.bsky.social · 8d

🚀 Big win for #ASCVD Prevention!
The VESALIUS-CV Phase 3 trial fullfilled its primary endpoints: #evolocumab significantly reduced CVD events in high-risk patients without prior AMI or stroke. 💥💓
This is a major leap forward for primary prevention!
zurl.co/SPJSp

LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints demonstrating that Repatha®...

www.prnewswire.com

Fotios Barkas @fotiosbarkas.bsky.social · 8d

📢 Υποβολή περιλήψεων – HAS 2025!
📝 Προθεσμία: 15/10/2025 | 📩 Αποδοχή: 1/11/2025

👉 zurl.co/wkyt1
#HAS2025 #Atherosclerosis #CardioResearch

11ο Πανελλήνιο Συνέδριο των Ομάδων Εργασίας της Ελληνικής Εταιρείας Αθηρσκλήρωσης

5-6 Δεκεμβρίου 2025 - Αθήνα

has2025.gr

Fotios Barkas @fotiosbarkas.bsky.social · Aug 9

👏 Well done Nikolaos - Gavriil Kolios, who is one of my PhD Students, and the rest of the team George Ntaios H Milionis #Stroke #ACS #LipidLowering #cholesterol

Fotios Barkas @fotiosbarkas.bsky.social · Aug 9

👌 We know what to do after acute #coronary events

🤔 But what about stroke 🧠, the leading cause of #disability worldwide?

🧐 What’s the evidence 📚, which drugs 💊, and how low to go 📉?

Enjoy 👇 www.thieme-connect.com/products/ejo...

1 3

Fotios Barkas @fotiosbarkas.bsky.social · Jul 21

#EASYOUNGFELLOWS #EAS
#SGLT2i #Atherosclerosis #Diabetes #CVPrevention

Fotios Barkas @fotiosbarkas.bsky.social · Jul 21

🚨 Just out in the American Journal of Preventive Cardiology!
Our latest review on the atheroprotective power of #SGLT2 inhibitors 💥
From 🧠 #stroke to #CAD & #PAD — SGLT2i are changing the game in #CVD prevention!
Read it here!
doi.org/10.1016/j.aj...

1 1 2

Fotios Barkas @fotiosbarkas.bsky.social · Jun 17

📖 Read the full paper here:
🔗 www.jacc.org/doi/10.1016/...

👏 Huge credit to all INTERASPIRE Investigators for this global contribution to cardiovascular prevention!

#LipoproteinA #Lp_a #CVDPrevention #CardioTwitter #Lipidology #JACC #GlobalHealth

Fotios Barkas @fotiosbarkas.bsky.social · Jun 17

4️⃣ Most patients with high Lp(a) also had poorly controlled traditional risk factors.

📈 In regions lacking access to novel therapies, risk factor management must be improved several fold to offset Lp(a)-related residual risk.

1

Fotios Barkas @fotiosbarkas.bsky.social · Jun 17

3️⃣ Traditional lipids don’t predict Lp(a).
LDL-C, non–HDL-C, and ApoB did not correlate with Lp(a) across most of its range.

✅ Bottom line: Measure Lp(a) directly—don’t rely on traditional lipids.

1

Fotios Barkas @fotiosbarkas.bsky.social · Jun 17

2️⃣ Eligibility for emerging Lp(a)-lowering therapies:

▪️ 6.2% at ≥200 nmol/L
▪️ 13.0% at ≥150 nmol/L

⚠️ Marked variation across WHO regions and even between countries within the same region.

1

Fotios Barkas @fotiosbarkas.bsky.social · Jun 17

1️⃣ Median Lp(a): 32 nmol/L
👉 82.4% of patients were below the 125 nmol/L threshold typically linked to increased ASCVD risk.
🧠 Suggests that Lp(a)’s contribution to CHD may be more complex than previously assumed.

1

Fotios Barkas @fotiosbarkas.bsky.social · Jun 17

🚨 Recently in @jaccjournals.bsky.social Key findings from the INTERASPIRE study on Lp(a) in 3,928 CHD patients across 13 countries 🌍

A 🧵 on what we found & what it means for future Lp(a)-lowering therapies:

1 2

Fotios Barkas @fotiosbarkas.bsky.social · Jun 7

🔜 See you next year—and don’t forget:
📍 December 2025 in Athens: Panhellenic Congress of HAS Working Groups
📍 May 2026 in Athens: EAS Congress

Fotios Barkas @fotiosbarkas.bsky.social · Jun 7

🎓 And just like that, our Summer School has come to an end!
A heartfelt THANK YOU to all our amazing speakers and the engaged scholars who enriched the sessions with their questions and insights! 🙌
What a truly fruitful and inspiring experience!

#Dyslipidemia #SummerSchool #HAS2025 #EAS #Lipids

1

Fotios Barkas @fotiosbarkas.bsky.social · Jun 6

🎉 The HAS Summer School has just kicked off!!
🧑‍🎓Time to dive deep into #lipoprotein metabolism with Prof Alexandros Tselepis and the epidemiology of secondary #dyslipidemias with Prof Demosthenes Panagiotakos!

#HellenicAtherosclerosisSociety #HAS2025

1

Fotios Barkas @fotiosbarkas.bsky.social · Jun 2

us02web.zoom.us/webinar/regi...

#Lipids #Hypertriglyceridemia #triglycerides #CVD #cardiovasculardisease

Fotios Barkas @fotiosbarkas.bsky.social · Jun 2

🚨 Don’t miss this must-attend webinar!
🎯 Innovations in Severe Hypertriglyceridemia Management & Cardioprotection
🎙️ Keynote: Prof. Daniel Gaudet
📅 Wednesday, June 4, 2025
🕕 17:00 CET
💻 Online | Registration required
🔗 Reserve your spot now!
Registration link below!

1

Fotios Barkas @fotiosbarkas.bsky.social · May 31

📍See you in Athens this December & at #EASCongress2026 in May!
#atherosclerosis #HAS #CVD #EAS2025 #Cyprus #Greece

1

Fotios Barkas @fotiosbarkas.bsky.social · May 31

🎉 The 1st Pan-Cypriot Atherosclerosis Congress 🇨🇾 concluded with great success!
A flawlessly organized event with high-level scientific content and warm hospitality.
Representing the Hellenic Atherosclerosis Society 🇬🇷, we extend a big thank you to our colleagues in Cyprus!

1 1

Fotios Barkas @fotiosbarkas.bsky.social · May 31

A deep dive into secondary causes of #dyslipidemia, interactive sessions & the latest in #CardiovascularPrevention in a closed meeting with chosen scholars from #Greece and #Cyprus!💡

#Atherosclerosis #Syros2025 #MedicalEducation #Lipids #SummerSchool #ConferreMedConnect

1

Fotios Barkas @fotiosbarkas.bsky.social · May 31

🚨 Coming up: 18th Summer School of the Hellenic Atherosclerosis Society
🗓 June 6–7, 2025 | 📍Syros, Greece 🇬🇷

1 1

Fotios Barkas @fotiosbarkas.bsky.social · May 22

How you can get a grant?
Tips from the best! Judith Sluimer Keith Channon
New #AtheroTalk podcast now available!
Live from #EASCONGRESS2025!!
ENJOY! 👇👇👇👇👇👇👇👇👇👇🤔
open.spotify.com/episode/4ngq...

E14 LIVE from EAS 2025: Behind the Grant Application with Judith Sluimer & Keith Channon

AtheroTalk · Episode

open.spotify.com

Fotios Barkas @fotiosbarkas.bsky.social · May 6

What does EAS Young Fellows Programm mean?? It means SCIENCE, PASSION, FRIENDSHIP & a touch of ART — all in one squad! Loving the energy at #EASCongress2025 #EASYoungFellows #MyEAS2025 #AtheroTalk

2 6

Fotios Barkas @fotiosbarkas.bsky.social · May 6

We are waiting for you at the EAS Stage!!
Social media and the physician: What can we harness?
A powerful reminder of the digital tools at our fingertips to educate, connect, and inspire!
#EAS2025 #EASCongress2025 #EASSoMe

2

Fotios Barkas @fotiosbarkas.bsky.social · May 6

We’ve just kicked off the E-HEALTH, AI AND BIG DATA workshop at #EAS2025 — where cutting-edge digital health meets clinical impact!

#EASCongress2025 #EASSoMe

1